TITLE

Localisation and characterisation of dystrophin in the central nervous system of controls and patients with Duchenne muscular dystrophy

AUTHOR(S)
Uchino, M; Teramoto, H; Naoe, H; Yoshioka, K; Miike, T; Ando, M
PUB. DATE
April 1994
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Apr1994, Vol. 57 Issue 4, p426
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66027739

 

Related Articles

  • Dystrophin, Utrophin, and Muscular Dystrophy. Chevron, Marie-Pierre // New England Journal of Medicine;3/2/95, Vol. 332 Issue 9, p612 

    A response by Marie-Pierre Chevron in response to his article on a patient with Duchenne's muscular dystrophy and an absence of dystrophin is presented.

  • Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Tinsley, Jonathon M.; Potter, Allyson C. // Nature;11/28/1996, Vol. 384 Issue 6607, p349 

    Reports on the expression of a utrophin transgene at high levels in a dystrophin-deficient mdx mouse. The suggestion that a systemic upregulation of utrophin in duchenne muscular dystrophy (DMD) patients may lead to the development of an effective treatment for the disorder.

  • Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Ervasti, J.M.; Ohlendieck, K. // Nature;5/24/1990, Vol. 345 Issue 6273, p315 

    Demonstrates that four glycoproteins are integral components of the dystrophin complex and that the concentration of one of these is greatly reduced in Duchenne muscular dystrophy patients. Dystrophin-glycoprotein complex; Analysis of dystrophic muscle; Discussion.

  • Autonomic regulation in muscular dystrophy. Angelini, Corrado; Di Leo, Rita; Cudia, Paola // Frontiers in Physiology;Sep2013, Vol. 4, p1 

    The article discusses the assessment of autonomic nervous system (ANS) function in muscular dystrophies. Topics discussed include the relationship between ANS and cardiac mortality, types of muscular dystrophies such as Duchenne (DMD) and Becker (BMD) muscular dystrophies, myotonic dystrophy,...

  • Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Anthony, Karen; Cirak, Sebahattin; Torelli, Silvia; Tasca, Giorgio; Feng, Lucy; Arechavala-Gomeza, Virginia; Armaroli, Annarita; Guglieri, Michela; Straathof, Chiara S.; Verschuuren, Jan J.; Aartsma-Rus, Annemieke; Helderman-van den Enden, Paula; Bushby, Katherine; Straub, Volker; Sewry, Caroline; Ferlini, Alessandra; Ricci, Enzo; Morgan, Jennifer E.; Muntoni, Francesco // Brain: A Journal of Neurology;Dec2011, Vol. 134 Issue 12, p3544 

    Duchenne muscular dystrophy is caused by mutations in the DMD gene that disrupt the open reading frame and prevent the full translation of its protein product, dystrophin. Restoration of the open reading frame and dystrophin production can be achieved by exon skipping using antisense...

  • LEARNING AND TRANSFER IN TWO PERCEPTUAL-MOTOR SKILLS IN DUCHENNE MUSCULAR DYSTROPHY. Nakafuji, Atsushi; Tsuji, Keichiro // Perceptual & Motor Skills;Oct2001, Vol. 93 Issue 2, p339 

    Examines the perceptual-motor learning and bilateral transfer in Duchenne muscular dystrophy. Deterioration of the mediating process of perceptual-motor coordination; Alteration of the central nervous system process; Acquisition of the tracing skill with preferred hand.

  • Severe childhood autosomal recessive muscular dystrophy, mental subnormality and chorea. Khadilkar, Satish V.; Menezes, Krishe M.; Singh, Rakesh K.; Hegde, Madhuri R. // Neurology India;Sep2006, Vol. 54 Issue 3, p293 

    Severe childhood autosomal recessive muscular dystrophy (SCARMD) is characterized by a severe Duchene muscular dystrophy like phenotype. Most such cases represent alpha or gamma sarcoglycanopathies. Mental subnormality is very uncommon and other central nervous system deficits have not been...

  • POSTERS TOPIC F: CHARACTERISATION OF MUTATIONS.  // European Journal of Human Genetics;Jul99 Supplement 1, Vol. 7, p115 

    The article presents abstracts of medical research. They include "Multiple endocrine neoplasia type II B," "Identification of a 58-bp insertion coupled with a duplication of exon 44 in the dystrophin transcripts of a Duchenne Muscular Dystrophy patient," and "Studies of a contribution of the...

  • NICE asks for more evidence to justify cost of ataluren.  // PharmacoEconomics & Outcomes News;Oct2015, Vol. 739 Issue 1, p32 

    The article reports that the British National Institute for Health & Clinical Excellence (NICE) is seeking more evidence for the justification of the treatment cost of ataluren (Translama) for patients with Duchenne muscular dystrophy (DMD) with a nonsense mutation in the dystrophin gene.

  • Corrigendum: Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients.  // Molecular Therapy;Nov2013, Vol. 21 Issue 11, p2130 

    A correction is to the article "Reading Frame Correction by Targeted Genome Editing Restores Dystrophin Expression in Cells From Duchenne Muscular Dystrophy Patients" that was published in a 2013 issue is presented.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics